FDA identifies eight deaths tied to Amgen's Tavneos
Max Bayer / endpoints - The FDA on Tuesday flagged more than 70 cases of severe liver injury and eight deaths associated with Amgen’s autoimmune treatment Tavneos, but the company said it previously notified the agency about the risk of ...
AI Summary: The FDA has tied eight patient deaths to Amgen’s drug Tavneos, prompting heightened regulatory review and industry concern. Reports outline safety signals and agency actions as clinicians and manufacturers reassess risk‑benefit profiles, while regulators weigh labeling, monitoring or other interventions to protect patients.
Related Stories
FDA launches individualized therapy framework for ultra-rare diseases / 4 months
FDA makes one pivotal trial the default for drug approvals / 4 months
FDA refuses to review Moderna mRNA flu vaccine application / 5 months
FDA rejects Atara cell therapy for Epstein–Barr virus complications / 5 months
Boehringer gains fast approval for first‑line lung cancer drug via voucher program / 4 months
FDA clears first new sunscreen ingredient in two decades / 28 days
FDA commissioner Marty Makary resigns amid mounting scrutiny / 1 month
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Long COVID, Novo Nordisk, Pfizer, Pancreatic Cancer and look for the RSS link.
StackHealth Time Machine